Dissection of the mechanism of this interaction will provide novel insights on how these molecules regulate BCSC self-renewal upon RON activation and will support the use of RON inhibitors as a therapeutic strategy to target the cross-regulation between these two self-renewal pathways in breast cancer. The gene discussed is MST1R; the disease is breast carcinoma.